Captopril-Associated Neutropenia

Cooper, Richard A.

doi:10.1001/archinte.1983.00350040049004

Cited by 76 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, it has become clear that ACE is also a regulator of hemopoietic stem cell proliferation. This was first indicated by the observation that occasional hypertensive patients treated with specific inhibitors of ACE activity developed granulocytopenia, aplastic anemia, and pancytopenia [13, , , , –18]. In vitro and in vivo studies in mice have since shown that inhibition of ACE activity inhibits the proliferation of primitive hematopoietic cells [11, 19, , , , –24].…”

Section: Introductionmentioning

confidence: 99%

A Role for Angiotensin‐Converting Enzyme in the Characterization, Enrichment, and Proliferation Potential of Adult Murine Pituitary Colony‐Forming Cells

et al. 2006

View full text Add to dashboard Cite

Recently, we described a rare cell type within the adult murine pituitary gland with progenitor cell hallmarks (PCFCs). PCFCs are contained exclusively within a subpopulation of cells that import fluorescent ␤-Ala-Lys-N-AMCA (7-amino-4-methylcoumarin-3-acetic acid). Herein, we investigate the utility of cell surface molecules angiotensin-converting enzyme (ACE) and stem cell antigen-1 (Sca-1) to further enrich for PCFCs. ACE and Sca-1 were expressed on 61% and 55% of AMCA ؉ CD45 ؊ CD31 ؊ cells, respectively, and coexpressed on 38%. ACE

show abstract

Section: Introductionmentioning

confidence: 99%

A Role for Angiotensin‐Converting Enzyme in the Characterization, Enrichment, and Proliferation Potential of Adult Murine Pituitary Colony‐Forming Cells

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Recently, enalapril has been established in long-term therapy because of its longer half-life and its more gradual onset of action [19][20][21][22][23][24]. The potential risks of the hitherto conventional high-dosage angiotensin-converting enzyme inhibitors are recognized [25][26][27][28][29], particularly the detrimental effects of long-acting enalapril on renal function [30]. Only one study tried to reduce the dosage to 10 mg/day, and it was successful [4].…”

Section: Discussionmentioning

confidence: 99%

Low-dose enalapril in severe chronic heart failure

Brilla

Krämer

Hoffmeister

et al. 1989

Cardiovasc Drug Ther

View full text Add to dashboard Cite

In a 3-month prospective, single-blind, controlled trial, 38 patients in New York Heart Association functional class III-IV were assigned to group E (n = 19): enalapril 5 mg/day in addition to the previous therapy with digitalis and diuretics, or group C (n = 19): continuation of the previous therapy. In group E, 79% of the patients improved by at least one NYHA functional class after 3 months. In group C, the functional class did not change and four patients died. The echocardiographically determined end-diastolic diameter of the left ventricle decreased in group E from 72 +/- 8 mm to 63 +/- 6 mm (p less than 0.001), and the scintigraphically determined ejection fraction of the left ventricle increased from 33 +/- 18% to 40 +/- 19% (p less than 0.002). In contrast, no significant change was found in group C. Plasma-renin activity increased in group E from 8.2 +/- 1.8 ng/ml h to 29.7 +/- 14 ng/ml h (p less than 0.001), and plasma aldosterone decreased from 47.7 +/- 7.6 ng/dl to 19.9 +/- 4.8 ng/dl (p less than 0.01). In group C no significant change occurred. Comparing the actual changes (deltas) of the NYHA functional class (p less than 0.02), end-diastolic diameter and ejection fraction of the left ventricle, plasma-renin activity, and plasma aldosterone (p less than 0.0001), a significant difference between the two groups was found. Thus, low-dose enalapril resulted in a significant improvement of the NYHA functional class in patients with severe chronic heart failure, accompanied by an improvement in left ventricular function and a decrease in secondary aldosteronism.

show abstract

“…The risk of neutropenia is different among various patient groups; while it is infrequent in patients with uncom plicated hypertension, it is dangerous in patients with renal dysfunction [3]. In patients with normal creati nine levels and no evidence of collagen-vascular dis ease, the frequency of neutropenia was 0.02%.…”

Section: Discussionmentioning

confidence: 99%

“…Several adverse reactions were reported since 1979 in cluding cardiovascular, renal, cutaneous, and mu cous membrane side effects [1,2], Neutropenia with myeloid hypoplasia has been reported in up to 0.4% among patients with creatinine levels above 2.0 mg/dl [3]. Agranulocytosis has been observed in several cases.…”

Section: Introductionmentioning

confidence: 99%

“…Agranulocytosis has been observed in several cases. All these were transient and reversible by dis continuation of the medication [3][4][5][6][7], 1 patient devel oped fatal pancytopenia but he was suspected of hav ing an underlying blood dyscrasia [8]. We wish now to report a case of transient aplastic anemia associated with captopril administration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation